NAUT Nautilus Biotechnology Inc
Price (delayed)
$0.8921
Market cap
$112.54M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.56
Enterprise value
$115.37M
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics
Highlights
Nautilus Biotechnology's debt has decreased by 12% YoY and by 3.4% QoQ
The quick ratio has contracted by 10% YoY but it has grown by 4.9% from the previous quarter
The equity has decreased by 21% YoY and by 7% from the previous quarter
Nautilus Biotechnology's net income has decreased by 11% YoY
Key stats
What are the main financial stats of NAUT
Market
Valuations
Earnings
Shares outstanding
126.15M
Market cap
$112.54M
Enterprise value
$115.37M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$81.48M
Net income
-$70.78M
EBIT
-$70.78M
EBITDA
-$64.43M
Free cash flow
-$61.27M
Per share
Balance sheet
Liquidity
EPS
-$0.56
EPS diluted
-$0.56
Free cash flow per share
-$0.49
Book value per share
$1.66
Revenue per share
$0
TBVPS
$1.94
Total assets
$242.74M
Total liabilities
$34.01M
Debt
$30.48M
Equity
$208.73M
Working capital
$125.19M
Debt to equity
0.15
Current ratio
17.4
Quick ratio
17.02
Net debt/EBITDA
-0.04
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-26.6%
Return on equity
-30.9%
Return on invested capital
-26.3%
Return on capital employed
-30.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NAUT stock price
How has the Nautilus Biotechnology stock price performed over time
Intraday
7.47%
1 week
-0.9%
1 month
-31.38%
1 year
-67.08%
YTD
-46.9%
QTD
3.61%
Financial performance
How have Nautilus Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$81.48M
Net income
-$70.78M
Gross margin
N/A
Net margin
N/A
Nautilus Biotechnology's net income has decreased by 11% YoY
Nautilus Biotechnology's operating income has decreased by 7% YoY
Growth
What is Nautilus Biotechnology's growth rate over time
Valuation
What is Nautilus Biotechnology stock price valuation
P/E
N/A
P/B
0.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NAUT's EPS is down by 10% year-on-year
The stock's price to book (P/B) is 88% less than its 5-year quarterly average of 4.0 and 62% less than its last 4 quarters average of 1.3
The equity has decreased by 21% YoY and by 7% from the previous quarter
Efficiency
How efficient is Nautilus Biotechnology business performance
The return on equity has declined by 38% year-on-year and by 7% since the previous quarter
NAUT's return on assets is down by 36% year-on-year and by 7% since the previous quarter
The ROIC is down by 20% year-on-year and by 8% since the previous quarter
Dividends
What is NAUT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NAUT.
Financial health
How did Nautilus Biotechnology financials performed over time
Nautilus Biotechnology's total assets has decreased by 21% YoY and by 7% from the previous quarter
NAUT's total liabilities is down by 15% year-on-year and by 6% since the previous quarter
Nautilus Biotechnology's debt is 85% lower than its equity
The equity has decreased by 21% YoY and by 7% from the previous quarter
Nautilus Biotechnology's debt to equity has increased by 15% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.